|Work hours||Add information|
|About||Community engagement is an essential part of the STREAM trial and acknowledges the importance of The Good Participatory Guidelines for TB Drug Trials. STREAM community engagement creates opportunities for dialogue and cooperation among stakeholders.|
|Mission||This Facebook page is a forum for individuals involved in community engagement for the STREAM trial to discuss their experiences and observations with others, and to ask questions and share feedback. Updates will be posted regularly and we encourage everyone to join in the discussions.|
The STREAM clinical trial is testing the effectiveness of shortened treatment regimens for multidrug-resistant tuberculosis (MDR-TB). STREAM Stage 1 is evaluating a nine-month shortened treatment regimen against the standard 20 to 24-month treatment regimen. Stage 2 of STREAM studies two additional regimens: an all-oral nine-month regimen and a six-month regimen, both of which include the novel anti-TB medicine bedaquiline.
Clinical research needs to fulfil the health-related needs of the community and, as such, community structures should always be considered when trials are implemented. In addition, members of communities involved in the trial need to understand the research itself, as well as ethics and regulatory requirements. To achieve this in a meaningful way, a structure of communication needs to be established through community engagement. The STREAM trial has developed a community engagement plan to facilitate that communication structure.
The STREAM trial is being implemented by The International Union Against Tuberculosis and Lung Disease and its affiliate Vital Strategies. Stage 1 of the STREAM Trial was funded primarily through the TREAT TB cooperative agreement with the US Agency for International Development (USAID), with additional funding from the UK Medical Research Council and the UK Department for International Development (DFID). STREAM Stage 2 is jointly funded by USAID and Janssen Pharmaceuticals.